Waqas Ahmed

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 19

Top Topics

Health Insurance

Patients With Inflammatory Bowel Disease

Allergic Rhinitis

Top Venues

Journal of comparative effectiveness research

Journal of medical economics

Scientific reports

ClinicoEconomics and outcomes research : CEOR

This page only lists publications with an associated author ORCID identifier.

Publications

Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock
Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO 2 emissions in Sweden. Scientific reports 14 (1) (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research 13 (3) (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research 13 (3) (2024)
Chantal Mathieu, Waqas Ahmed, Pieter Gillard, Ohad Cohen, Robert A Vigersky, Simona de Portu, Asli Zeynep Ozdemir Saltik
The Health Economics of Automated Insulin Delivery Systems and the Potential Use of Time in Range in Diabetes Modeling: A Narrative Review. Diabetes technology & therapeutics 26 (S3) (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research 13 (3) (2024)
Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock
Modelling the Costs of Sublingual Immunotherapy versus Subcutaneous Immunotherapy Based on Clinical Appointments and Impacts of Patient Travel in Sweden. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Tariq H Iqbal, Nicholas Alexander Kennedy, Anjan Dhar, Waqas Ahmed, Richard F Pollock
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England. Journal of medical economics 27 (1) (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research 13 (3) (2024)
Tariq H Iqbal, Nicholas Kennedy, Anjan Dhar, Waqas Ahmed, Richard F Pollock
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England. Journal of medical economics (2024)
Fengkui Zhang, Aizong Shen, Waqas Ahmed, Richard F Pollock
A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China. Advances in therapy (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research (2024)
Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock
Modelling the Costs of Sublingual Immunotherapy versus Subcutaneous Immunotherapy Based on Clinical Appointments and Impacts of Patient Travel in Sweden. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Tariq H Iqbal, Nicholas Alexander Kennedy, Anjan Dhar, Waqas Ahmed, Richard F Pollock
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England. Journal of medical economics 27 (1) (2024)
Hamza Alshannaq, Richard F Pollock, Michael Joubert, Waqas Ahmed, Gregory J Norman, Peter M Lynch, Stéphane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Journal of comparative effectiveness research 13 (3) (2024)
Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock
Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO 2 emissions in Sweden. Scientific reports 14 (1) (2024)
Lars-Olaf Cardell, Thomas Sterner, Waqas Ahmed, Andreas Kallsoy Slættanes, Mikael Svärd, Richard F Pollock
Modelling the impact of sublingual immunotherapy versus subcutaneous immunotherapy on patient travel time and CO 2 emissions in Sweden. Scientific reports 14 (1) (2024)
Kristin Grabe-Heyne, Christof Henne, Isaac Odeyemi, Johannes Pöhlmann, Waqas Ahmed, Richard F Pollock
Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK. Journal of medical economics 26 (1) (2023)
Hamza Alshannaq, Greg Cogswell, Richard F Pollock, Waqas Ahmed, Greg J Norman, Peter M Lynch, Stephane Roze
Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose and intermittently scanned continuous glucose monitoring in people with type 1 diabetes receiving multiple daily insulin injections in Denmark. Diabetes, obesity & metabolism (2023)
Kristin Grabe-Heyne, Christof Henne, Isaac Odeyemi, Johannes Pöhlmann, Waqas Ahmed, Richard F Pollock
Evaluating the cost-utility of intravesical bacillus calmette-guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK. Journal of medical economics (2023)